

## Neurodevelopmental Screening in High risk Infants Using Denver Developmental Screening Test II

Dr. Kamala Rani Kothapally\*

Department of Pediatrics Medical College of India, India

### Introduction

Advances in Perinatal care and establishment of improved neonatal services have increased the survival rates of many high-risk newborns in developing countries. Developmental delay is anticipated in these babies [1]. Delay in normal development is a predictor of neurodevelopmental disorders like cerebral palsy, mental retardation and various learning disabilities. Various causes attributed to developmental delay and there are different clinical presentations, depending on nature of insult [2]. There may be associated problems such as different forms of learning disabilities, seizures, difficulties in feeding, growth, vision and hearing. Numerous studies have shown that there is a high incidence of chronic morbidities and adverse neurodevelopmental outcomes among high-risk infants. This highlights the need for a follow up care service that would ensure systematic monitoring of the general health and neurodevelopmental after discharge from the hospital [3]. Early identification of developmental delay is very important to start early interventional services there by improving quality of life. Ideal developmental assessment tools are elaborate and require expertise in the field. Simplified tools need to be devised to help the pediatrician working under constraints. Denver Developmental Screening Test II (DDST II) is a simple, easy to perform, open test which can be performed in age group 0-6 years [4].

### Objectives

#### Primary

To determine the incidence of developmental delay in high risk infants.

#### Secondary

To determine the demographic and clinical factors for their risk of leading to developmental delay

To estimate the proportion of high-risk infants with abnormal hearing screen

To estimate the proportion of high-risk neonates with ROP developing adverse visual

### Methodology

#### Study population and study design

This prospective observational study of high-risk infants was conducted in the department of Pediatrics at Armed Forces Medical College and Command Hospital (Southern Command), Pune, a tertiary care, referral and teaching hospital for a period of eighteen months from January 2020 to July 2022 [5]. All the infants fulfilling the eligibility criteria and under follow up in high risk follow up clinic or admitted in the Command Hospital during this period were recruited in the study after written informed consent of parents/ guardian. Permission for the study was granted from the Institutional Ethics Committee [6] (Table 1).

#### Inclusion criteria

All infants attending for follow-up in high-risk infant clinic will be

enrolled for study after parents' consent:

Term low birth weight (LBW) neonates  $\leq$  1800 grams

Preterm neonates  $\leq$  34 week, irrespective of their weights

Neonatal seizures

Severe neonatal jaundice

Ventilation including CPAP  $\geq$  48 hours

Neonatal sepsis and Meningitis

Twins: MCDA discordant twin

Prolonged or refractory hypoglycemia

Preterm neonate with IVH / NEC/ PDA/ BPD

For determining incidence sample size calculation is as enumerated below:-

#### Sample size calculation

P1= Probability of the disease in the exposed = 30% i.e. 0.3

P2= Probability of the disease in non-exposed = 5% i.e. 0.05

Confidence = 95% 4. RR=P1/P2 i.e. 6

E (relative precision) = 30% i.e. 0.3

Alpha = 0.05 7. Beta = 0.80

Total Sample size required is 36 infants.

#### Data analysis

All the data generated was noted on a proforma as per Annexure – A. A excel data sheet (Annexure – B) was generated to statistically analyze the complete data collected which was analyzed using the SPSS Ver. 22 software. Descriptive statistics would be used to analyze the baseline variables. The numerical variables such as biochemical investigation parameters and age of patients were expressed as mean + standard deviation (SD) or Median (range) as per data distribution pattern. The categorical variables were presented as absolute values or percentage/ proportions [7].

\*Corresponding author: Dr. Kamala Rani Kothapally, Department of Pediatrics Medical College of India, India, E-mail: kkamala510@gmail.com

Received: 01-June-2023, Manuscript No: nnp-23-97120; Editor assigned: 07-June-2023, Pre-QCNo: nnp-23-97120(PQ); Reviewed: 21-June-2023, QCNo: nnp-23-97120; Revised: 23-June-2023, Manuscript No: nnp-23-97120(R); Published: 30-June-2023, DOI: 10.4172/2572-4983.1000323

Citation: Kothapally KR (2023) Neurodevelopmental Screening in High risk Infants Using Denver Developmental Screening Test II. Neonat Pediatr Med 9: 323.

Copyright: © 2023 Kothapally KR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Table 1:** Primary outcome parameter.

Objective	Outcome Variable	Definition of Outcome Variable	Method of measurement
Incidence of Developmental Delay	Gross motor, Fine motor, Language and Social domain test items scored as Passed-P, Failed-F, Refused-R, Caution-C or Delayed-D	Normal or Suspect	DDST II

**Table 2:** Secondary outcome parameter.

Objective	Outcome Variable	Definition of Outcome Variable	Method of Measurement
Demographic and Clinical risk factor assessment	Gestation; Weight; Gender; Growth status; Growth restricted twin; Admission diagnosis; Postnatal morbidities	Standard definitions as given in literature	Data analysis
To estimate the proportion of high-risk neonates with ROP developing adverse visual outcomes	ROP screening result	Type 1 ROP or Type 2 ROP	Indirect Ophthalmoscopy (IDO)
Proportion of high-risk infants with abnormal hearing screen	Hearing screening result	Pass or Retest	OAE & BERA

The two-sample t-test (Student's t) was used for analyzing the quantitative variables with normal distribution. The Chi ( $\chi^2$ ) square test was used where distribution was skewed and for categorical variables [8] (Table 2).

Descriptive statistics: Frequency of demographic and clinical characteristics of the enrolled population [9].

### Result

A total of 42 patients were evaluated for the study. Of these total 42 patients, 4 participants fulfilled the exclusion criteria whereas consent could not be obtained for 2 patients [10]. 36 high risk infants under follow up were finally recruited in the study after written informed consent from parents/ guardians. The flow of enrolment of participants in the study is depicted in the flow diagram below: (Figure 1)

#### Maternal factors vs abnormal DDST II:

When maternal factors were plotted against suspect status on DDST II, the maternal B+ blood group, gestational diabetes and gestational age less than 28 weeks were noted to be significantly correlated with p values of 0.005, 0.003 and 0.029 respectively (Table 3).

### Conclusions

Out of a total 42 patients, 4 participants fulfilled the exclusion criteria whereas consent could not be obtained for 2 patients. 36 high risk infants under follow up were finally recruited in the study after written informed consent from parents/ guardians.


The mean maternal age was  $30.3 \pm 4.6$  years. The commonest gestational age of mothers was 32 - 35 weeks with 15 participants followed by five mothers with gestational age of 23 - 26 weeks.

Gravidity of G1 and G2 were present in 15 and 13 participants respectively.

The common blood groups were O+ in 16 mothers, B+ in seven mothers and A+ in 6 mothers.

The common maternal comorbidities were hypertension including preeclampsia in seven mothers followed by gestational diabetes in four mothers and PPROM in two mothers. The commonest AFI was noted to be 11 - 15 in 19 mothers.

24 mothers in the cohort delivered baby by LSCS as compared to 12 mothers delivering baby by normal vaginal delivery. 20 babies



**Figure 1:** Graphical presentation of study methodology.

Maternal Factors	DDST II		p-value
	Suspect	Normal	
Maternal age >30	4	15	0.79
Gravida $\geq 3$	2	5	0.49
Mother blood gp B+	4	3	0.005
GA $\leq 28$ wks	4	5	0.029
No AN steroids	3	9	0.55
LSCS delivery	6	18	0.23
GDM	3	1	0.003

**Table 3:** Maternal factors Vs Abnormal DDST II.

were males and 16 babies were females. Delayed cord clamping was performed for 28 children in the cohort.

Children had APGAR of 5-7 followed by 10 children with APGAR of 3-4 at 1 minute. At 5 minutes 26 children had APGAR between 7-9. The commonest perinatal morbidity noted in children was respiratory

distress in 23 cases followed by sepsis/ meningitis in 7 cases and HIE in 4 cases. even children each were born ELBW (weight of 0.5 to. 1 kg) and VLBW (weight of 1 to 1.5 kgs). 16 children were born low birth weight between 1.5 to 2.5 kg.

Delay in gross and fine motor milestones was noted in three children each. Five children had language delay and four had delaying social and adaptive milestones on performing DDST. Six children were noted to manifest ROP in one or both eyes. Only three children with ROP required laser treatment (\*). None in the cohort had any hearing loss to have suspect status.

When maternal factors were plotted against suspect status on DDST II, the maternal B+ blood group, gestational diabetes and gestational age less than 28 weeks were noted to be significantly correlated with p values of 0.005, 0.003 and 0.029 respectively.

The neonatal factors of APGAR < 2 at 1' (p-value 0.013), severe respiratory distress (p-value 0.001), sepsis/ meningitis (p-value 0.005), severe jaundice (p-value 0.004) and hypoglycemia (p-value 0.004) were noted to be significantly correlated with suspect status.

The incidence of developmental delay in high-risk infants was 19.4% or 194 per 1000 high risk cases.

DDST II test consistently picked up suspect cases with developmental delay since early infancy within 3 months of age. Hence is proved to be excellent evaluation to pick up developmental delay in high-risk cases.

## References

1. Branson RD (2013) Asynchrony and Dyspnea. *Res Care* 58:973–989.
2. Van Kaam, Anton (2011) Lung-Protective Ventilation in Neonatology. *Neonat* 99:338–341.
3. Howard Stein, Kimberly Firestone, BS, Peter C, Rimensberger (2018) Synchronized Mechanical Ventilation Using Electrical Activity of the Diaphragm in Neonates.
4. Mallik M, Watson AR (2008) Antenatally detected urinary tract abnormalities more detection but less action. *Pediatr Nephrol. Neonat* 23: 897-904.
5. Woodward M, Frank D (2002) Postnatal management of antenatal hydronephrosis. *BJU Int* 89: 149-156.
6. Ocheke IE, Antwi S, Gajjar P, McCulloch MI, Nourse P (2014) Pelvi-ureteric junction obstruction at Red Cross Children's Hospital, Cape Town: a six year review. *Arab J Nephrol Trans* 7: 33-36.
7. Capello SA, Kogan BA, Giorgi LJ (2005) Kaufman RP. Prenatal ultrasound has led to earlier detection and repair of ureteropelvic junction obstruction. *J Urol* 174: 1425-1428.
8. Johnston JH, Evans JP, Glassberg KI, Shapiro SR (1977) Pelvic hydronephrosis in children: a review of 219 personal cases. *J Urol* 117: 97-101.
9. Williams DI, Kenawi MM (1976) The prognosis of pelviureteric obstruction in childhood: a review of 190 cases. *Eur Urol* 2: 57-63.
10. Lebowitz RL, Griscom NT (1977) Neonatal hydronephrosis: 146 cases. *Radiol Clin North Am* 15: 49-59.